Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer. Its products pipeline also comprises BION-1301, a B-select monoclonal antibody novel therapy for multiple myeloma; A PRoliferation-Inducing Ligand for the treatment of multiple myeloma, chronic lymphocytic leukemia, and colorectal carcinoma; CD27, a co-stimulatory receptor for the treatment of cancer; and CTLA-4 for the treatment of advanced melanoma and other cancers. The company's pLADD program is based on proprietary attenuated strains of Listeria that have been engineered to express tumor neo antigens that are specific to an individual patient's tumor. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Janssen Biotech, Inc, and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone510-848-4400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$17.24 million
Profitability
Miscellaneous
Employees162
Next Earnings Date3/7/2019 (Estimated)
OptionableOptionable
Aduro BioTech (NASDAQ:ADRO) Frequently Asked Questions
What is Aduro BioTech's stock symbol?
Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO."
How were Aduro BioTech's earnings last quarter?
Aduro BioTech Inc (NASDAQ:ADRO) issued its earnings results on Tuesday, October, 30th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.31) by $0.02. The biotechnology company had revenue of $3.06 million for the quarter, compared to analyst estimates of $4.59 million. Aduro BioTech had a negative net margin of 591.66% and a negative return on equity of 50.03%. View Aduro BioTech's Earnings History.
When is Aduro BioTech's next earnings date?
What price target have analysts set for ADRO?
7 brokers have issued 12-month target prices for Aduro BioTech's shares. Their predictions range from $6.00 to $15.00. On average, they anticipate Aduro BioTech's stock price to reach $9.86 in the next year. This suggests a possible upside of 141.1% from the stock's current price. View Analyst Price Targets for Aduro BioTech.
What is the consensus analysts' recommendation for Aduro BioTech?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aduro BioTech in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aduro BioTech.
What are Wall Street analysts saying about Aduro BioTech stock?
Here are some recent quotes from research analysts about Aduro BioTech stock:
- 1. According to Zacks Investment Research, "Aduro's three distinct technology platforms are being utilized by several companies to develop treatments for several cancer indications. The company’s collaboration agreements with large pharma companies — Novartis and Johnson & Johnson — not only validate its research platforms but also enhance its financial position, providing it with adequate funds. However, with no approved products in Aduro’s portfolio, the company heavily depends on funds generated from collaboration and license agreements, government grants as well as other payments for the development of its pipeline candidates. Thus, an inability to secure sufficient funding could hinder Aduro’s pipeline progress. Shares of the company have underperformed the industry so far this year." (12/31/2018)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating, and $8.30 price target. Our target is based on our clinical net present value (NPV) model, which derives value from across Aduro’s assets but primarily for ADU-S100. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (12/19/2018)
Has Aduro BioTech been receiving favorable news coverage?
News headlines about ADRO stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aduro BioTech earned a news sentiment score of 1.3 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Are investors shorting Aduro BioTech?
Aduro BioTech saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 1,572,918 shares, a drop of 56.1% from the January 15th total of 3,581,701 shares. Based on an average trading volume of 686,652 shares, the short-interest ratio is currently 2.3 days. Approximately 3.5% of the shares of the company are sold short. View Aduro BioTech's Current Options Chain.
Who are some of Aduro BioTech's key competitors?
Some companies that are related to Aduro BioTech include Corcept Therapeutics (CORT), Esperion Therapeutics (ESPR), Spectrum Pharmaceuticals (SPPI), Phibro Animal Health (PAHC), TherapeuticsMD (TXMD), Amphastar Pharmaceuticals (AMPH), Wave Life Sciences (WVE), Vanda Pharmaceuticals (VNDA), Deciphera Pharmaceuticals (DCPH), Puma Biotechnology (PBYI), CannTrust (CNTTF), Alder Biopharmaceuticals (ALDR), Kiniksa Pharmaceuticals (KNSA), Tricida (TCDA) and Rhythm Pharmaceuticals (RYTM).
What other stocks do shareholders of Aduro BioTech own?
Who are Aduro BioTech's key executives?
Aduro BioTech's management team includes the folowing people:
- Mr. Stephen T. Isaacs, Chairman, CEO & Pres (Age 70)
- Dr. Andrea van Elsas, Chief Scientific Officer (Age 51)
- Mr. Blaine E. Templeman, Corp. Devel. Head, Chief Legal Officer and Sec. (Age 53)
- Ms. Jennifer Lew, Chief Financial Officer (Age 46)
- Ms. Alexandra Santos, Exec. Director of Corp. Affairs & Investor Relations
When did Aduro BioTech IPO?
(ADRO) raised $119 million in an initial public offering on Wednesday, April 15th 2015. The company issued 7,000,000 shares at a price of $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.
Who are Aduro BioTech's major shareholders?
Aduro BioTech's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.71%), Baillie Gifford & Co. (4.61%), Artal Group S.A. (1.26%), Northern Trust Corp (0.91%), Geode Capital Management LLC (0.79%) and Dimensional Fund Advisors LP (0.71%). Company insiders that own Aduro BioTech stock include Blaine Templeman, Dirk G Brockstedt, Elsas Andrea Van, Gregory W Schafer, Jennifer Lew, Natalie Sacks, Stephen T Isaacs and Thomas W Dubensky. View Institutional Ownership Trends for Aduro BioTech.
Which institutional investors are selling Aduro BioTech stock?
ADRO stock was sold by a variety of institutional investors in the last quarter, including United Services Automobile Association and Northern Trust Corp. Company insiders that have sold Aduro BioTech company stock in the last year include Blaine Templeman, Elsas Andrea Van, Jennifer Lew, Natalie Sacks and Stephen T Isaacs. View Insider Buying and Selling for Aduro BioTech.
Which institutional investors are buying Aduro BioTech stock?
ADRO stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Artal Group S.A., Two Sigma Investments LP, Dimensional Fund Advisors LP, BlackRock Inc., Two Sigma Advisers LP, Bank of America Corp DE and Geode Capital Management LLC. View Insider Buying and Selling for Aduro BioTech.
How do I buy shares of Aduro BioTech?
Shares of ADRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aduro BioTech's stock price today?
One share of ADRO stock can currently be purchased for approximately $4.09.
How big of a company is Aduro BioTech?
Aduro BioTech has a market capitalization of $324.75 million and generates $17.24 million in revenue each year. The biotechnology company earns $-91,860,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. Aduro BioTech employs 162 workers across the globe.
What is Aduro BioTech's official website?
How can I contact Aduro BioTech?
Aduro BioTech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-848-4400 or via email at [email protected]
MarketBeat Community Rating for Aduro BioTech (NASDAQ ADRO)
MarketBeat's community ratings are surveys of what our community members think about Aduro BioTech and other stocks. Vote "Outperform" if you believe ADRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
